TABLE 2.
BC-negative, SepsiTest-positive results
| Patient no. (diagnosis) | Parameter | Result by sampling timea |
Interpretation |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-ECMO | 8 h | 1 day | 3 days | 5 days | 7 days | 9 days | 11 days | Probable | Possible | Indeterminate | ||
| 8 (ARDSc, pneumonia, pneumothorax) | SepsiTestOtherb | Corynebacterium spp. (99.7) | − | − | − | CNS (100) Enterococcus spp. | CNS (99.7), K. oxytoca/E. cloacae (100) | CNS (99.6), M. osloensis (100) | CNS (100) | CNS | K. oxytoca/E. cloacae | Corynebacterium spp., M. osloensis |
| AB treatment | Dif, Mox, Flu [until 11 days] | Mer, Van [until 11 days] | Met [until 11 days] | |||||||||
| 9 (broncho-adeno carcinoma, pneumonia, sepsis/septic shock, pulmonal edema) | SepsiTest | − | − | − | − | − | CNS (99.7) | CNS (99.2) | CNS | |||
| Other | ||||||||||||
| AB treatment | Mer, Van, Flu [until 9 days] | |||||||||||
| 10 (chronical heart insufficiency (endocarditis), colitis ulcerosa) | SepsiTest | Corynebacterium spp. (99.2) | − | − | Corynebacterium spp. (99.7) | − | ND | − | Corynebacterium spp. | |||
| Other | E. cloacae | S. maltophilia | ||||||||||
| AB treatment | Dap [until 9 days] | Tob [until 7 days] | ||||||||||
| 11 (bronchiolitis obliterans, ARDS, pneumonia, pneumothorax) | SepsiTest | CNS (99.7) | − | CNS (99.7) | Streptococcus spp. (100) | − | − | CNS | Streptococcus spp. | |||
| Other | CNS | CNS, Haemophilus parainfluenzae | ||||||||||
| AB treatment | Cas, Mer, Mox [until 7 days] | Van, Met [until 7 days] | Tob | |||||||||
| 12 (heart insufficiency, pulmonary hypertony) | SepsiTest Other | − | − | − | − CNS | CNS (99.7), Corynebacterium spp. (100) | − | CNS | Corynebacterium spp. | |||
| AB treatment | Flu [until 7 days] | Van | ||||||||||
| 13 (heart and respiratory insufficiency, idiopathic pulmoarterial hypertony, renal failure) | SepsiTest | − | − | − | − | S. aureus (100) | S. aureus | |||||
| Other | S. aureus | |||||||||||
| AB treatment | Mer, Tob, Flu | |||||||||||
| 14 (myocardial infarct, cardial shock, cardiovascular disease, renal failure) | SepsiTest Other | − Enterococcus spp., C. albicans | − | − | Enterococcus cecorum (99.4), A. baumannii (100) | E. cecorum, A. baumannii | ||||||
| AB treatment | Amp [until 8 h] | Mer [until 3 days] | Van [until 3 days] | |||||||||
| 15 (prosthetic mitral valve endocarditis, pneumonia, renal failure) | SepsiTest | E. faecalis (99.6) | E. faecalis | |||||||||
| Otherd | ||||||||||||
| AB treatment | Gen, Amp | |||||||||||
Pre-ECMO, approximately 30 min before start of ECMO support; −, negative result; CNS, coagulase-negative staphylococci; MRSA, methicillin-resistant Staphylococcus aureus. Numbers in parentheses are percent sequence identities to the reference (unidirectional sequencing) of 16S (450-bp) and 18S (320-bp) rDNA amplicons. Duration of treatment is given in square brackets. The coverage of all sequences analyzed is 100%; read length is 380 to 400 bp (16S) and 240 to 260 bp (18S). Amp, ampicillin; Ani, anidulafungin; Cas, caspofungin; Cef, cefuroxime; Cot, cotrimoxazole; Dap, daptomycin; Dif, diflucan; Ert, ertapenem; Ery, erythromycin; Flu, flucloxacillin; Gen, gentamicin; Lin, linezolid; Mer, meropenem; Met, metronidazole; Mox, moxifloxacin; Taz, tazobactam; Tob, tobramycin; Una, sultamicillin (Unacid); Van, vancomycin.
Other, swabs from tracheal exudates, perfusates, wounds, pharynx, catheter, urine, or bronchoalveolar lavage or cultures of tissue biopsies.
ARDS, acute respiratory distress syndrome.
E. faecalis in BC 3 weeks before ECMO support.